Fludarabine BEAM pretreated autologous peripheral blood stem cell transplantation in Non-Hodgkin's lymphoma.

Objective To investigate the effect of fludarabine combined with BEAM regimen in pretreatment of autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma. Methods 55 patients with non Hodgkin lymphoma were given BEAM regimen (carmustine Ara-C pretreatment (Ma Falan), control group n=27) and fludarabine (observation group, n=28). Treatment effects were compared between the two groups. Results The observation group of patients after transplantation in the treatment of white blood cell minimum down time less than 0.5×109/L and granulocyte returned to normal time and the control group there were significant differences compared with patients and lower than that of control group (P 0.05), but the total number of CD4 lymphocytes after transplantation compared with before treatment decreased, NK cells (natural killer cells) total compared with before treatment increased significantly (P 0.05). Two groups of patients with recurrence rate compared with significant difference (P<0.05). Conclusion Fludarabine combined with BEAM pretreatment type peripheral blood stem cell transplantation in the treatment of patients with non-Hodgkin lymphoma is good. Key words: Non-Hodgkin lymphoma; Fludarabine; BEAM pretreatment; Autologous peripheral blood stem cell transplantation